Skip to main content
KOREA ARLICO PHARM CO.,LTD. logo

KOREA ARLICO PHARM CO.,LTD. — Investor Relations & Filings

Ticker · 260660 ISIN · KR7260660006 KO Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2025-02-26 AGM Information
Country KR South Korea
Listing KO 260660

About KOREA ARLICO PHARM CO.,LTD.

https://jazzarlico.tradekorea.com/compa…

Korea Arlico Pharm Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes prescription (ETC) and over-the-counter (OTC) drugs, medical devices, and oriental medical preparations, with a specialization in generic pharmaceuticals. Operating from a KGMP-certified facility, it focuses on continuous innovation to improve human health. The company serves its domestic market and exports its products to numerous countries, with the goal of expanding its global presence.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for Holding a General Meeting on a Concentrated Date'. It explains why the company, Alvogen Korea, is holding its annual general meeting on a date that coincides with the peak period for shareholder meetings, as identified by the KOSDAQ Association. This is a specific regulatory disclosure requirement in the Korean market and does not fit into categories like AGM-R (presentation materials) or PSI (proxy solicitation). It is a standard regulatory announcement, thus falling under RNS.
2025-02-26 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Allico Pharmaceutical. It contains the agenda for the 34th Annual General Meeting, including items such as financial statement approval, director re-election, and dividend approval. It also includes detailed management information, financial statements, and proxy-related details. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes.
2025-02-26 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Aliko Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director re-election, and dividend approval) for the upcoming Annual General Meeting. This document serves as the official notification and solicitation of shareholder participation for the meeting, which falls under the category of Proxy Solicitation & Information Statement.
2025-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Alco Pharmaceutical regarding a significant change in financial structure (revenue/profit/loss) exceeding 15% for a non-large corporation. It provides a summary of financial results (revenue, operating profit, net income) and the reasons for the change. This is a standard 'Earnings Release' (ER) format used in the Korean market (DART system) to announce preliminary financial results before the final audit report is published. FY 2024
2025-02-12 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Aliko Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend yield, the total dividend amount, and the record date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and major contracts (such as collateral agreements) of major shareholders and their special relations. This falls under the category of Major Shareholding Notification (MRQ).
2024-12-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.